Olanzapine-induced weight gain: Chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution

European Journal of Pharmacology

Volumn 585, Issue 1, 2008, Pages 130-136

  van der Zwaal, Esther M ^a   Luijendijk, Mieneke C M ^a   Adan, Roger A H ^a   la Fleur, Susanne E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Animal model; Body weight; Drug administration; Food intake; Olanzapine; Osmotic minipumps

Indexed keywords

OLANZAPINE;

ANIMAL MODEL; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; FOOD PREFERENCE; IN VITRO STUDY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; EATING; INFUSION PUMPS, IMPLANTABLE; MALE; PHARMACEUTICAL SOLUTIONS; RATS; RATS, WISTAR; WEIGHT GAIN;

EID: 42249086778     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.11.078     Document Type: Review

References (37)

1. Aichhorn W., Whitworth A.B., Weiss E.M., and Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?. Drug Safety 29 (2006) 587-598
2. Allison D.B., Mentore J.L., Heo M., Weiden P.J., Cappelleri J.C., and Chandler L.P. Weight gain associated with conventional and newer antipsychotics: a meta-analysis. Schizophr. Res. 36 (1999) 353
3. Aravagiri M., Teper Y., and Marder S.R. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm. Drug Dispos. 20 (1999) 369-377
4. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr. Scand. 100 (1999) 3-16
5. Berridge K.C. Food reward: brain substrates of wanting and liking. Neurosci. Biobehav. Rev. 20 (1996) 1-25
6. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., and Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14 (1996) 87-96
7. Callaghan J.T., Bergstrom R.F., Ptak L.R., and Beasley C.M. Olanzapine - pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. 37 (1999) 177-193
8. Catlow J.T., Barton R.D., Clemens M., Gillespie T.A., Goodwin M., and Swanson S.P. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J. Chromatogr., B Biomed. Appl. 668 (1995) 85-90
9. Chiu J.A., and Franklin R.B. Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. J. Pharm. Biomed. Anal. 14 (1996) 609-615
10. Fontaine K.R., Heo M., Harrigan E.P., Shear C.L., Lakshminarayanan M., Casey D.E., and Allison D.B. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 101 (2001) 277-288
11. Gervasini G., Vizcaino S., Herraiz A.G., Benitez J., and Carrillo J.A. Applicability of an assay for routine monitoring of highly variable concentrations of olanzapine based on HPLC with mass spectrometric detection. Clin. Chem. 49 (2003) 2088-2091
12. Gunaratna P.C., Kissinger P.T., Kissinger C.B., and Gitzen J.F. An automated blood sampler for simultaneous sampling of systemic blood and brain microdialysates for drug absorption, distribution, metabolism, and elimination studies. J. Pharmacol. Toxicol. Methods 49 (2004) 57-64
13. Kapur S., and Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 52 (2001) 503-517
14. Kapur S., Vanderspek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 305 (2003) 625-631
15. Kassahun K., Mattiuz E., Nyhart E., Obermeyer B., Gillespie T., Murphy A., Goodwin M., Tupper D., Callaghan J.T., and Lemberger L. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab. Dispos. 25 (1997) 81-93
16. Kiang T.K.L., Ensom M.H.H., and Chang T.K.H. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 106 (2005) 97-132
17. Leucht S., Wahlbeck K., Hamann J., and Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361 (2003) 1581-1589
18. Li M., Budin R., Fleming A.S., and Kapur S. Effects of chronic typical and atypical antipsychotic drug treatment on maternal behavior in rats. Schizophr. Res. 75 (2005) 325-336
19. Liston H.L., Markowitz J.S., and Devane C.L. Drug glucuronidation in clinical psychopharmacology. J. Clin. Psychopharmacol. 21 (2001) 500-515
20. Masaki T., and Yoshimatsu H. The hypothalamic H-1 receptor: a novel therapeutic target for disrupting diurnal feeding rhythm and obesity. Trends Pharmacol. Sci. 27 (2006) 279-284
21. Meltzer H.Y., Park S., and Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13591-13593
22. Mir S., and Taylor D. Atypical antipsychotics and hyperglycaemia. Int. Clin. Psychopharmacol. 16 (2001) 63-73
23. Olesen O.V., and Linnet K. Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs. J. Chromatogr., B Biomed. Sci. Appl. 714 (1998) 309-315
24. Parkinson A., Mudra D.R., Johnson C., Dwyer A., and Carroll K.M. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol. 199 (2004) 193-209
25. Reynolds G.P., Zhang Z.J., and Zhang X.B. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359 (2002) 2086-2087
26. Scherk H., Pajonk F.G., and Leucht S. Second-generation antipsychotic agents in the treatment of acute mania - a systematic review and meta-analysis of randomized controlled trials. Arch. Gen. Psychiatry 64 (2007) 442-455
27. Schwartz J.B. The influence of sex on pharmacokinetics. Clin. Pharmacokinet. 42 (2003) 107-121
28. Seager M.A., Barth V.N., Phebus L.A., and Rasmussen K. Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology 181 (2005) 126-133
29. Tecott L.H., Sun L.M., Akana S.F., Strack A.M., Lowenstein D.H., Dallman M.F., and Julius D. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 374 (1995) 542-546
30. Turrone P., Remington G., Kapur S., and Nobrega J.N. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol. Psychiatry 57 (2005) 406-411
31. Wang H.X., Li D., Xu C.J., and Liu X. [Sex-difference on flutamide metabolism in rat liver microsomal cytochrome P450 1A2]. Yao Xue. Xue. Bao. 37 (2002) 608-610
32. Weiden P.J., Mackell J.A., and McDonnell D.D. Obesity as a risk factor for antipsychotic noncompliance. Schizophr. Res. 66 (2004) 51-57
33. Weiss U., Marksteiner J., Kemmler G., Saria A., and Aichhorn W.F. Effects of age and sex on olanzapine plasma concentrations. J. Clin. Psychopharmacol. 25 (2005) 570-574
34. Wirshing D.A., Wirshing W.C., Kysar L., Berisford M.A., Goldstein D., Pashdag J., Mintz J., and Marder S.R. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry 60 (1999) 358-363
35. Wirshing D.A., Boyd J.A., Meng L.R., Ballon J.S., Marder S.R., and Wirshing W.C. The effects of novel antipsychotics on glucose and lipid levels. J. Clin. Psychiatry 63 (2002) 856-865
36. Wrighton S.A., and Ring B.J. Predicting drug interactions and pharmacokinetic variability with in vitro methods: the olanzapine experience. Drug Metab. Rev. 31 (1999) 15-28
37. Yamada M., Miyakawa T., Duttaroy A., Yamanaka A., Moriguchi T., Makita R., Ogawa M., Chou C.J., Xia B., Crawley J.N., Felder C.C., Deng C.X., and Wess J. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 410 (2001) 207-212